Biocardia stock.

Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,450,986 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...Nov 29, 2023 · The BioCardia, Inc. stock price fell by -0.92% on the last day (Wednesday, 29th Nov 2023) from $0.686 to $0.680. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 11.30% from a day low at $0.639 to a day high of $0.711. The price has fallen in 8 of the last 10 days and is down by -36.45% for this period. BioCardia Inc ( BCDA) is lower by Wednesday morning, with the stock declining -4.67% in pre-market trading to 1.02. BCDA's short-term technical score of 100 indicates that the stock has traded more bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 123 out of 146 industries, the …The estimated Net Worth of Simon H Stertzer is at least $1.35 Millón dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,277,638 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.

BioCardia Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BCDA updated stock price target summary.The BioCardia, Inc. stock price fell by -0.92% on the last day (Wednesday, 29th Nov 2023) from $0.686 to $0.680. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 11.30% from a day low at $0.639 to a day high of $0.711. The price has fallen in 8 of the last 10 days and is down by -36.45% for this period.

BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates Zacks - Wed Nov 9, 2022 . BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?BioCardia, Inc. reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Ladies and gentlemen, thank you for standing by and welcome to the ...

BioCardia Inc BCDA shares are down after the company released interim efficacy results in the phase 3 pivotal CardiAMP cell therapy heart failure trial.. For the first tier, all-cause death ...BioCardia Inc. Real-Time Quotes. 0.62. BATS BZX Real-Time Price. As of 12:24pm ET. -0.065 / -9.49%. Today’s Change. 0.36. Today ||| 52-Week Range.SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor …Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...

Nov 15, 2023 · BioCardia (NASDAQ:BCDA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment?We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.

BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...

Nov 14, 2023 · BioCardia Inc (BCDA) stock is unmoved 0% while the S&P 500 is higher by 1.44% as of 4:00 PM on Monday, Nov 13. BCDA is unmoved $0.00 from the previous closing price of $0.40 on volume of 39,170,298 shares. Over the past year the S&P 500 has gained 13.09% while BCDA has fallen -78.61%. BCDA lost -$0.63 per share the over the last 12 months. 2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval. 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Mr. Krasno BCDA stock SEC Form 4 insiders trading. Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.. The largest trade he's ever made was buying 80,000 units of BioCardia stock on …Find the latest BioCardia, Inc. (BCDA) stock quote, history, news and other vital information to help you with your stock trading and investing. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%?

Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ...Mr. Krasno BCDA stock SEC Form 4 insiders trading. Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.. The largest trade he's ever made was buying 80,000 units of BioCardia stock on …BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates Zacks - Wed Nov 9, 2022 . BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? BioCardia has received a go-ahead from the FDA for a first-in-human trial of a second version of its stem cell implants designed to help rescue patients from heart failure. The green light clears ...Nov 30, 2023 · BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million. The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ...

Nov 16, 2023 · SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ... 5 Sep 2023 ... Biocardia stock dropped from about $2 on July 21 to $1.10 on July 24, when the concerns of the DSMB were first revealed. After drifting down ...

A high-level overview of BioCardia, Inc. (BCDA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The latest update sent BioCardia’s stock down around 20%. (Paul Campbell/Getty Images) BioCardia’s dive into its paused phase 3 heart failure trial has failed to identify reasons to be ...When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.A new COVID variant, HV.1, is now dominant. These are its most common symptoms. Deer hunting is dying. That should worry you even if you don't hunt. The FDA approved BioCardia Inc's (NASDAQ: BCDA ...November 15, 2023 at 8:04 AM · 3 min read. Shares of BioCardia BCDA skyrocketed 168.2% on Tuesday after management announced that the FDA approved its proposed late-stage CardiAMP Heart Failure ...5 Sep 2023 ... Biocardia stock dropped from about $2 on July 21 to $1.10 on July 24, when the concerns of the DSMB were first revealed. After drifting down ...Shares of BioCardia Inc. sank 13.9% in morning trading Wednesday, after the developer of regenerative biologic therapies announced more stock sales in the wake of the 137.6% rocket ride over... Shares of BioCardia Inc. sank 13.9% in morning trading Wednesday, after the developer of regenerative biologic therapies announced more stock sales in the wake of the 137.6% rocket ride over...Overview News BioCardia Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-0.63 Market Cap $14.02 M 21.62 M Public Float 10.05 M Yield BCDA is...

6 hari yang lalu ... BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of ...

Stock analysis for BioCardia Inc (BCDA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Jul 24, 2023 · July 24, 2023. SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP ... BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ...Most recently, on Friday, May 26th, Peter Altman bought 6,200 shares of BioCardia stock. The stock was acquired at an average cost of $1.60 per share, with a total value of $9,920.00. Following the completion of the transaction, the chief executive officer now directly owns 469,239 shares of the company's stock, valued at $750,782.40.Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued.Mr. Fernandez BCDA stock SEC Form 4 insiders trading. Fernando has made over 1 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 14,277 units of BCDA stock worth $10,292 on 13 January 2018.. The largest trade he's ever made was exercising 14,277 units of …Dividends on BioCardia stock: dividend pay date calendar, dividend per share, dividend payment, dividend historical data, dividend policy, dividend news, dividend schedulet, dividend chart. ... BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is ...2023. 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. 14 Nov. 2023 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure. 2023 BioCardia Reports Third Quarter 2023 Business Highlights and …Jul 24, 2023 · July 24, 2023. SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP ... Simon Stertzer BCDA stock SEC Form 4 insiders trading. Simon has made over 15 trades of the BioCardia stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 166,666 units of BCDA stock worth $999,996 on 5 July 2019.. The largest trade he's ever made was buying 3,333,332 units of BioCardia stock on 24 …Shares of BioCardia (. BCDA Quick Quote. BCDA - Free Report) skyrocketed 168.2% on Tuesday after management announced that the FDA approved its proposed late-stage CardiAMP Heart Failure II study ...Nov 14, 2023 · A new COVID variant, HV.1, is now dominant. These are its most common symptoms. Deer hunting is dying. That should worry you even if you don't hunt. The FDA approved BioCardia Inc's (NASDAQ: BCDA ... 6 hari yang lalu ... BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected ...

BIOCARDIA, INC. 2002 STOCK PLAN . STOCK OPTION AGREEMENT . Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Option Agreement. I. NOTICE OF STOCK OPTION GRANT . Name: Address: 125 Shoreway Road, Suite B.Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, …BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Instagram:https://instagram. how to invest in penny shareswordpad alternativewestinghouse nuclear stockproduct management first steps by linkedin learning SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of …Nov 24, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo... itb holdingsiphone 15 deliveries Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000. zwu Get the latest BioCardia Inc (BCDA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, …